---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-067461"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2023-12-04T23:59:59+00:00"
generated_at: "2026-06-07T18:47:12.511246+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IDEAYA collaborates with Gilead for Phase 1 combo of IDE397 + Trodelvy in MTAP-deletion bladder cancer

## Summary
- IDEAYA and Gilead will evaluate IDE397 (MAT2A inhibitor) plus Trodelvy (Trop-2 ADC) in MTAP-deletion bladder cancer.
- MTAP-deletion prevalence in bladder cancer is ~26%, with no approved therapies for this population.
- IDEAYA sponsors the Phase 1 trial; Gilead provides Trodelvy at no cost; each party retains commercial rights to its own compound.
- IDEAYA is also evaluating IDE397 in an ongoing Phase 1/2 monotherapy and in a separate Amgen combination study.

## SEC filing metadata
- accession: 0000950170-23-067461
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2023-12-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000095017023067461/0000950170-23-067461-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000095017023067461/idya-20231129.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-067461
- JSON: https://secwatch.observer/filing/0000950170-23-067461.json
- Plain text: https://secwatch.observer/filing/0000950170-23-067461.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.